Addendum
Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15
Report documents
-
Addendum
Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15
Dossier assessment
Indication:
Adults with chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes mellitus
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.
Project details
- Project no.
- A23-70
- Commission
- Commission awarded on 11.07.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Kidneys and urinary system
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Finerenone (CKD stage 2 and 3) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed